Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Key Step in Precision Treatment: Detailed Explanation of CAR-T Apheresis for a Russian Patient at Jiahui International Hospital in Shanghai
Title:
Key Step in Precision Treatment: Detailed Explanation of CAR-T Apheresis for a Russian Patient at Jiahui International Hospital in Shanghai
Content:
Vladimir Borzenkov, a 68-year-old Russian patient from Saint Petersburg, recently underwent a crucial step in CAR-T therapy at Jiahui International Hospital in Shanghai – apheresis. This process involves collecting T cells from the patient’s body for further genetic modification and amplification. Vladimir expressed appreciation for the professionalism of the treatment team and the transparency of the treatment process, which not only alleviated his anxiety but also increased confidence in the success of the treatment. Jiahui Hospital utilized its advanced facilities and technology to provide Vladimir with a smooth and efficient apheresis experience, ensuring high-quality collection of T cells and laying a solid foundation for the next steps of treatment.
#CART #MultipleMyeloma #FUCASOapproval #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈
🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈
cancer fight
🌟Mr. C from California, USA
It’s yet another heartening piece of news as Mr. C from California, USA, undergoes cross-border treatment at Jiangsu Province People’s Hospital in China, successfully overcoming multiple myeloma and embracing a new lease on life! After meticulous treatment spanning one and a half months, Mr. C, accompanied by his loved ones, has made a successful recovery and been discharged from the hospital, becoming the first American patient to be successfully treated with CAR-T cell therapy for multiple myeloma in China.
🌞New treatment method
Mr. C, a 56-year-old American who is passionate about sports, discovered he had multiple myeloma after sustaining sports-related injuries. Despite enduring several unsuccessful treatment attempts, he refused to give up and began seeking treatment opportunities worldwide. However, the exorbitant cost of treating multiple myeloma in the USA deterred him. After comparing prices and data of CAR-T therapy for multiple myeloma between the USA and China, he ultimately decided to explore the new treatment method at Jiangsu Province People’s Hospital.
🌤Upon arriving in China,
Mr. C not only received meticulous care from medical staff but also had the opportunity to explore the scenic beauty of cities such as Nanjing, Suzhou, and Hangzhou, experiencing the unique cultural charm of China. During the CAR-T cell therapy treatment process, Mr. C underwent a life-threatening cytokine storm, but with the emergency intervention of the medical team, he successfully weathered the storm. Today, he has recovered and been discharged from the hospital, though slightly fatigued, he is still filled with hope and gratitude.
🔥Hope and Courage
Although Mr. C’s treatment has concluded, follow-up work will continue, with the medical team maintaining contact with his family doctor to closely monitor treatment effectiveness and subsequent conditions. As medical personnel, they sincerely hope that this treatment will provide Mr. C with more opportunities for survival.
☀️Mr. C also expressed his desire to revisit China, specifically Nanjing, to visit the experts and nurses who treated him, and of course, to continue savoring Chinese cuisine. This journey of treatment across continents not only granted Mr. C a new lease on life but also showcased the unity and dedication of medical personnel from both China and the USA. May this touching story inspire more people and bring forth more hope and courage!
⭐️CAR-T therapy
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
You can send electronic copies or photos of genetic testing reports and diagnostic reports to:
💌: doctor.huang@globecancer.com
📞WhatsApp 137 1795 9070
✨The Medical Department will contact you as soon as receive the reports.
#CARTtherapy #LymphomaTreatment #CompleteRemission #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Shanghai Hospital Achieves Complete Remission and Discharge of the 100th Patient with Relapsed/Refractory Lymphoma Treated with CAR-T Therapy
Shanghai Hospital Achieves Complete Remission and Discharge of the 100th Patient with Relapsed/Refractory Lymphoma Treated with CAR-T Therapy
Lymphoma
Ruijin Hospital,
affiliated with Shanghai Jiao Tong University School of Medicine, announced that with continuous exploration in clinical practice, experts have made progress in CAR-T cell therapy for lymphoma, benefiting an increasing number of patients. This advancement is of significant importance for further promoting and expanding the application of CAR-T therapy, allowing more patients to benefit from it.
Lymphoma
is a malignant tumor originating from the lymphatic hematopoietic system and encompasses a family of nearly a hundred different subtypes. Relapse and drug resistance pose major challenges for patients. CAR-T products have the potential to improve treatment outcomes and facilitate the broader application of CAR-T therapy among a wider range of patients in China.
CAR-T therapy
involves genetically modifying T cells to equip them with the ability to recognize tumors, enabling them to kill cancer cells in the body. If natural T cells can be likened to “ordinary soldiers,” then CAR-T cells can be considered as “special forces.” For cancer patients, the 5-year survival rate is an important milestone and a signal of cancer being cured. Achieving a 5-year survival implies that some cancer patients treated with CAR-T therapy can obtain long-term survival without further anticancer drug treatment, truly achieving the possibility of “cancer being cured.” Aunt Qin, the first patient enrolled in China’s CAR-T registered clinical trial in 2018, has achieved sustained complete remission for over 5 years and is about to enter the 6th year.
100th patient
At Ruijin Hospital, the 100th patient with relapsed/refractory lymphoma treated with CAR-T therapy has achieved complete remission and been discharged. The patient, Ms. Xu (alias), is a 41-year-old woman who now has a healthy complexion. She was initially diagnosed with follicular lymphoma and underwent chemotherapy and targeted therapy. However, the disease relapsed three months later, transforming into high-grade B-cell lymphoma. High-grade B-cell lymphoma is highly malignant with a poor prognosis. Professor Zhao Weili from the Hematology Department at Ruijin Hospital conducted a detailed analysis of Ms. Xu’s condition and developed a treatment plan for her. On November 22, 2023, after receiving CAR-T cell infusion, Ms. Xu showed complete remission of the tumor during the follow-up examinations at one month and three months.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
You can send electronic copies or photos of genetic testing reports and diagnostic reports to:
Email: doctor.huang@globecancer.com
or WhatsApp+8613717959070
The Medical Department will contact you as soon as receive the reports.
#CARTtherapy #LymphomaTreatment #CompleteRemission #RuijinHospital #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness